Merck: Aggressive M&A Efforts To Prepare For A Keytruda Patent Cliff [Seeking Alpha]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Seeking Alpha
Merck remains heavily reliant on Keytruda, now over 50% of sales, with patent expiry risks looming in 2028-2029 despite pipeline efforts. Recent M&A, including Cidara and Terns, increases net debt to ~$50B but maintains leverage at manageable levels given ~$27B EBITDA. I remain cautious at current valuation due to high expectations, increased leverage, and concentration risk, despite reasonable adjusted earnings and solid dividend yield. Looking for a helping hand in the market? Members of Value In Corporate Events get exclusive ideas and guidance to navigate any climate. Learn More » Sundry Photography/iStock Editorial via Getty Images Towards the end of the first quarter, Merck ( MRK announced a larger acquisition to ignite some appeal in its pipeline. This was the second-largest deal announced in recent times, as Merck is spending a combined $15 More on my IG service If you like to see more ideas, please subscribe to the Investing Group "Value in Corporate Events" he
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.Business Wire
- Merck & Co., Inc. (MRK) had its price target raised by JPMorgan Chase & Co. from $125.00 to $135.00. They now have an "overweight" rating on the stock.MarketBeat
- Trump Unveils Up to 100% Tariffs on Imported Medicines With Key Exemptions [Yahoo! Finance]Yahoo! Finance
- Trump's 100% tariffs on drugs could cost you more at the pharmacy [Los Angeles Times (CA)]Los Angeles Times
- Want to work for one of America's best companies? These 3 N.J. employers made the cut. [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 4/1/26 - Form 4
- 4/1/26 - Form 4
- 4/1/26 - Form 4
- MRK's page on the SEC website